Glucagon (1-29)

Glucagon (1-29) – Human, Porcine (CAS: 16941-32-5) for research on diabetes, obesity, and non-alcoholic fatty liver disease (NAFLD). GPCR superfamily is organized into three main classes, among which the secretin receptor family (class B) regulated by glucagon peptides. Glucagon receptor is a 62 kDa plasma membrane protein activated upon binding to glucagon. When HSQGTFTSDYSKYLDSRRAQDFVQWLMNT binds to its receptor, conformational changes occur, which leads to the activation of G proteins. This activation sets off a cascade of events, including adenylate cyclase activation and subsequent cyclic AMP (cAMP) production. The cellular response is further orchestrated by protein kinase A, initiating series of biochemical reactions. In previous studies, it is known that glucagon receptors are predominantly present in the liver and kidneys, with varying expressions in other vital organs. Interestingly, the way glucagon works in diabetes, obesity, and NAFLD has led to new areas of investigation, suggesting its potential use as therapeutic target. Glucagon(1-29) glucoregulatory peptide hormone can stimulate hepatic glucose production, modulate energy balance, and potentially influence appetite regulation.